Related Experiment Video

Updated: Aug 11, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

[Abnormal expression of caspase8,bcl-2 and cytochrome C in drug resistant lung cancer cell]

Yan-Ling Zhang1, Ji-Rong Yue, Bi-Rong Dong

  • 1Department of Geriatrics, West China Hospital, Sichuan, University, Chengdu 610041, China.

Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition
|December 13, 2005
PubMed
Abstract

Insights

Increased bcl-2 protein expression may drive chemotherapy resistance in lung cancer cells by suppressing apoptosis proteins like caspase8 and cytochrome C. This resistance appears to occur post-transcriptionally, not at the mRNA level.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Context:

  • Lung cancer remains a leading cause of cancer-related mortality worldwide.
  • Chemotherapy resistance is a major clinical challenge in treating lung cancer.
  • Understanding the molecular mechanisms of drug resistance is crucial for developing effective therapies.

Purpose:

  • To investigate the relationship between chemotherapy resistance in A549 lung cancer cells and the expression of apoptosis-related proteins (caspase8, bcl-2, cytochrome C) and bcl-2 mRNA.
  • To compare protein and mRNA expression levels between sensitive (A549S) and drug-resistant (A549R) A549 cell lines.

Summary:

  • Reverse transcription polymerase chain reaction (RT-PCR) and Western Blot were used to analyze caspase8, bcl-2, and cytochrome C protein and bcl-2 mRNA expression in A549S and A549R cells.
  • Results showed significantly higher caspase8 and cytochrome C protein expression and lower bcl-2 protein expression in A549S cells compared to A549R cells (P<0.05).
  • No significant difference in bcl-2 mRNA levels was observed between the two cell lines (P>0.05), suggesting post-transcriptional regulation.

Impact:

  • The findings suggest that elevated bcl-2 protein expression may contribute to chemotherapy resistance in lung cancer by inhibiting apoptosis.
  • This study highlights that bcl-2's role in drug resistance might be regulated at the translational or post-translational level, rather than at the mRNA level.
  • These insights could inform the development of novel therapeutic strategies targeting bcl-2 pathways to overcome chemotherapy resistance in lung cancer.

More Related Videos

Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation08:47

Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation

Published on: March 5, 2018

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity04:20

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity

Published on: February 9, 2024

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...